Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Fowler, Catherine Thiéblemont, Monalisa Ghosh et al.|Nature Medicine|2021Cited by 523
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic MelanomaReinhard Dummer, Dirk Schadendorf, Georgina V. Long et al.|Zurich Open Repository and Archive (University of Zurich)|2022Cited by 146
LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trialPaul Nathan, Dirk Schadendorf, Reinhard Dummer et al.|Annals of Oncology|2020Cited by 68